Wanbury Ltd Launches Coriminic Nasal And Pediatric Drops

The launch of Coriminic NS and Coriminic CPM marks Wanbury’s continued focus on pediatric care. With rising demand for child-friendly medicines, the company is expanding its product line to address respiratory discomfort and allergic symptoms in younger patients.  

Coriminic NS Nasal Drops  
Designed specifically for children, Coriminic NS nasal drops help relieve nasal congestion and improve breathing comfort. The formulation is tailored to be gentle yet effective, making it suitable for pediatric use.  

Coriminic CPM Pediatric Drops  
Coriminic CPM drops are introduced to manage allergy-related symptoms such as sneezing, runny nose, and irritation. The pediatric formulation ensures safe dosage and ease of administration for children.  

Market Outlook  
Analysts believe these launches will strengthen Wanbury’s position in the pediatric pharmaceutical segment. With increasing awareness of child health, the company’s new offerings are expected to gain traction among healthcare providers and parents.  

Key Highlights  

• Wanbury Ltd launches Coriminic NS nasal drops for children  
• Coriminic CPM drops introduced for pediatric use  
• Focus on respiratory and allergy relief in children  
• Strengthens Wanbury’s pediatric healthcare portfolio  
• Expected to boost market presence in child health segment  

Sources: Reuters, Business Standard, Economic Times